Erratum to: Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα: OA has Therapeutic Potential in AML (International Journal of Cancer, (2014), 134, 5, (1195-1206), 10.1002/ijc.28435);Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα

International Journal of Cancer

Volumn 134, Issue 5, 2014, Pages 1195-1206

  Hui, Hui ^a   Chen, Yan ^a   Yang, Hao ^a   Zhao, Kai ^a   Wang, Qian ^a   Zhao, Li ^a   Wang, Xiaotang ^b   Li, Zhiyu ^a   Lu, Na ^a   Guo, Qinglong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

AML; differentiation; oroxylin A; PPAR ; RXR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ARGININE; CALCITRIOL; CCAAT ENHANCER BINDING PROTEIN BETA; CD11B ANTIGEN; CD14 ANTIGEN; CELL NUCLEUS RECEPTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; HYDROGEN; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; OROXYLIN A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P21; RETINOBLASTOMA PROTEIN; RETINOIC ACID; RETINOID X RECEPTOR ALPHA; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; HYDROGEN BOND; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84890556061     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.32761     Document Type: Erratum

References (52)

1. Nowak D, Stewart D, Koeffler HP,. Differentiation therapy of leukemia: 3 decades of development. Blood 2009; 113: 3655-65.
2. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-4.
3. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85: 2643-53.
4. Kreutz M, Andreesen R, Krause SW, et al. 1,25-dihydroxyvitamin D3 production and vitamin D3 receptor expression are developmentally regulated during differentiation of human monocytes into macrophages. Blood 1993; 82: 1300-7.
5. Tontonoz P, Nagy L, Alvarez JG, et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
6. Konopleva M, Tsao T, Ruvolo P, et al. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 2002; 99: 326-35.
7. Koschmieder S, D'Alo F, Radomska H, et al. CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha. Blood 2007; 110: 3695-705.
8. Ren W, Qiao Z, Wang H, et al. Flavonoids: promising anticancer agents. Med Res Rev 2003; 23: 519-34.
9. Williams RJ, Spencer JP, Rice-Evans C,. Flavonoids: antioxidants or signalling molecules? Free Radic Biol Med 2004; 36: 838-49.
10. Kang SN, Lee MH, Kim KM, et al. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 2001; 61: 1487-95.
11. Zhang K, Guo QL, You QD, et al. Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. Cancer Sci 2008; 99: 689-95.
12. Zhang HW, Yang Y, Zhang K, et al. Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation. Eur J Pharmacol 2008; 591: 7-12.
13. Zhang J, Harrison JS, Uskokovic M, et al. Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol Oncol 2010; 28: 124-32.
14. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640-50.
15. Kersten S, Desvergne B, Wahli W,. Roles of PPARs in health and disease. Nature 2000; 405: 421-4.
16. Spiegelman BM, Flier JS,. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-89.
17. Auwerx J,. PPARgamma, the ultimate thrifty gene. Diabetologia 1999; 42: 1033-49.
18. Matsushima-Nishiwaki R, Okuno M, Adachi S, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001; 61: 7675-82.
19. Kanemura N, Tsurumi H, Okuno M, et al. Retinoid X receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of 9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leuk Res 2008; 32: 884-92.
20. Li HB, Chen F,. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 2005; 1074: 107-10.
21. Lanotte M, Martin-Thouvenin V, Najman S, et al. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991; 77: 1080-6.
22. Tomida M,. Induction of differentiation of WEHI-3B D+ leukemic cells transfected with differentiation-stimulating factor/leukemia inhibitory factor receptor cDNA. Blood 1995; 85: 217-21.
23. Frey BM, Hackett NR, Bergelson JM, et al. High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors. Blood 1998; 91: 2781-92.
24. Nurtjahja-Tjendraputra E, Fu D, Phang JM, et al. Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood 2007; 109: 4045-54.
25. Richardson DR, Milnes K,. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 1997; 89: 3025-38.
26. Liu W, Mu R, Nie FF, et al. MAC-related mitochondrial pathway in oroxylin-A-induced apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett 2009; 284: 198-207.
27. Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood 2007; 109: 315-22.
28. Hong J, Samudio I, Liu S, et al. Peroxisome proliferator-activated receptor gamma-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 2004; 145: 5774-85.
29. Gong Y, Yue J, Wu X, et al. NSPc1 is a cell growth regulator that acts as a transcriptional repressor of p21Waf1/Cip1 via the RARE element. Nucleic Acids Res 2006; 34: 6158-69.
30. Mu R, Qi Q, Gu H, et al. Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. Mol Carcinog 2009; 48: 1159-69.
31. Griffin JD, Spertini O, Ernst TJ, et al. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol 1990; 145: 576-84.
32. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6: 137-43.
33. Tsao T, Kornblau S, Safe S, et al. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Res 2010; 70: 4949-60.
34. Zuo Y, Qiang L, Farmer SR,. Activation of CCAAT/enhancer-binding protein (C/EBP) alpha expression by C/EBP beta during adipogenesis requires a peroxisome proliferator-activated receptor-gamma-associated repression of HDAC1 at the C/EBP alpha gene promoter. J Biol Chem 2006; 281: 7960-7.
35. Nerlov C,. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol 2007; 17: 318-24.
36. Yamazaki K, Shimizu M, Okuno M, et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells-phosphorylated RXR alpha is a critical target for colon cancer management. Gut 2007; 56: 1557-63.
37. Adachi S, Okuno M, Matsushima-Nishiwaki R, et al. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002; 35: 332-40.
38. Shankaranarayanan P, Rossin A, Khanwalkar H, et al. Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO. Cancer Cell 2009; 16: 220-31.
39. Chou TC,. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-6.
40. Tsiftsoglou AS, Pappas IS, Vizirianakis IS,. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther 2003; 100: 257-90.
41. Raelson JV, Nervi C, Rosenauer A, et al. The PML/RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88: 2826-32.
42. Garcia-Bates TM, Lehmann GM, Simpson-Haidaris PJ, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. PPAR Res 2008; 2008: 834612.
43. Nakagawa K, Kishida H, Arai N, et al. Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-A(y) mice. Biol Pharm Bull 2004; 27: 1775-8.
44. Ding L, Jin D, Chen X,. Luteolin enhances insulin sensitivity via activation of PPARgamma transcriptional activity in adipocytes. J Nutr Biochem 2010; 21: 941-7.
45. Hassan M, El Yazidi C, Landrier JF, et al. Phloretin enhances adipocyte differentiation and adiponectin expression in 3T3-L1 cells. Biochem Biophys Res Commun 2007; 361: 208-13.
46. Gutsch R, Kandemir JD, Pietsch D, et al. CCAAT/enhancer-binding protein beta inhibits proliferation in monocytic cells by affecting the retinoblastoma protein/E2F/cyclin E pathway but is not directly required for macrophage morphology. J Biol Chem 2011; 286: 22716-29.
47. Wang LH, Yang XY, Zhang X, et al. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma cross talk with NF-kappaB and C/EBP. Blood 2007; 110: 4373-84.
48. Hamm JK, Park BH, Farmer SR,. A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. J Biol Chem 2001; 276: 18464-71.
49. Cao X, Liu W, Lin F, et al. Retinoid X receptor regulates Nur77/TR3-dependent apoptosis [corrected] by modulating its nuclear export and mitochondrial targeting. Mol Cell Biol 2004; 24: 9705-25.
50. Macoritto M, Nguyen-Yamamoto L, Huang DC, et al. Phosphorylation of the human retinoid X receptor alpha at serine 260 impairs coactivator(s) recruitment and induces hormone resistance to multiple ligands. J Biol Chem 2008; 283: 4943-56.
51. Tarrade A, Bastien J, Bruck N, et al. Retinoic acid and arsenic trioxide cooperate for apoptosis through phosphorylated RXR alpha. Oncogene 2005; 24: 2277-88.
52. Gianni M, Parrella E, Raska I, Jr, et al. P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcription. EMBO J 2006; 25: 739-51.